{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:04:11Z","timestamp":1784531051992,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Introduction: Abnormal serum potassium levels are a common issue in patients with heart failure with reduced ejection fraction (HFrEF), limiting the use of prognostically beneficial therapies. The primary aim of this study was to characterise the HFrEF population according to baseline potassium levels and to assess their impact on medium- to long-term prognosis. Methods: A retrospective study was conducted on a cohort of consecutive patients with HFrEF recruited at our centre. Patients were classified according to baseline serum potassium levels into: Group 1 (&lt;3.5 mEq\/L), Group 2 (3.5\u20135.0 mEq\/L), and Group 3 (&gt;5.0 mEq\/L). Prognostic impact was assessed in terms of HF readmissions, HF mortality and all-cause mortality. Results: A total of 409 patients were analysed. The median age was 69 years [IQR 59\u201377], with a predominance of male patients (74.1%). There were 26 patients (6.36%) with hypokalaemia, 365 (89.24%) with normokalaemia, and 18 (4.4%) with hyperkalaemia. Group 1 showed a higher prevalence of diabetes mellitus (69.2% vs. 47.4% vs. 33.4%; p = 0.043) and a greater proportion of patients with \u22652 previous admissions for HF (25% vs. 10.5% vs. 0%; p = 0.008). No differences were observed regarding echocardiographic parameters, markers of congestion, or HFrEF treatment. After a median follow-up of 60 months, no significant differences were found between groups in rates of HF readmissions, HF mortality and all-cause mortality. Conclusions: Patients with hypokalaemia exhibited a higher prevalence of diabetes mellitus and previous HF admissions. In our population, no differences were observed between groups in the use of prognostically beneficial therapies or in outcomes in terms of HF rehospitalisations and mortality.<\/jats:p>","DOI":"10.3390\/medsci14030402","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:09:09Z","timestamp":1784527749000},"page":"402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Baseline Potassium Abnormalities in Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4976-9150","authenticated-orcid":false,"given":"Alvaro","family":"Roldan-Guerra","sequence":"first","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-7332","authenticated-orcid":false,"given":"Jorge","family":"Perea-Armijo","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7369","authenticated-orcid":false,"given":"Rafael","family":"Gonz\u00e1lez-Manzanares","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-0823","authenticated-orcid":false,"given":"Juan Carlos","family":"Castillo-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Crespin-Crespin","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-9051","authenticated-orcid":false,"given":"Manuel","family":"Pan-\u00c1lvarez Ossorio","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-5044","authenticated-orcid":false,"given":"Jos\u00e9","family":"L\u00f3pez-Aguilera","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Reina Sofia University Hospital, 14004 Cordoba, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, IMIBIC (Instituto Maimonides de Investigacion Biomedica de Cordoba), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.recesp.2019.05.004","article-title":"Hiperpotasemia en pacientes con insuficiencia cardiaca en Espa\u00f1a y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term","volume":"73","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_3","first-page":"253","article-title":"Prevalence and incidence of hyperkalaemia in the Spanish population with heart failure with reduced ejection fraction: A systematic review and populational relevance","volume":"218","author":"Delgado","year":"2018","journal-title":"Rev. Cl\u00ednica Esp. (Engl. Ed.)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.repc.2022.05.002","article-title":"Potassium and disease-modifying therapy for heart failure with reduced ejection fraction: The beginning of a beautiful friendship?","volume":"41","year":"2022","journal-title":"Rev. Port. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Skogestad, J., and Aronsen, J.M. (2018). Hypokalemia-Induced Arrhythmias and Heart Failure: New Insights and Implications for Therapy. Front Physiol., 9.","DOI":"10.3389\/fphys.2018.01500"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-020-10039-9","article-title":"Serum potassium and heart failure: Association, causation, and clinical implications","volume":"26","author":"Sfairopoulos","year":"2021","journal-title":"Heart Fail Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: A cohort study from the Swedish Heart Failure Registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: The DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"(2021). KDIGO 2021, Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int., 99, S1\u2013S87.","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal Definition and Classification of Heart Failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"106962","article-title":"Heart failure with reduced ejection fraction: Influence of gender on clinical characteristics, cardiac remodeling and neurohormonal response","volume":"164","year":"2025","journal-title":"Med. Cl\u00ednica (Engl. Ed.)"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Perea-Armijo, J., L\u00f3pez-Aguilera, J., Gonz\u00e1lez-Manzanares, R., Pericet-Rodriguez, C., Castillo-Dom\u00ednguez, J.C., Heredia-Campos, G., Rold\u00e1n-Guerra, \u00c1., Urbano-S\u00e1nchez, C., Barreiro-Mesa, L., and Aguayo-Ca\u00f1o, N. (2023). The worsening of heart failure with reduced ejection fraction: The impact of the number of hospital admissions in a cohort of patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12186082"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0300-8932(09)70898-X","article-title":"El anciano con cardiopat\u00eda terminal","volume":"62","author":"Rexach","year":"2009","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.recesp.2014.10.016","article-title":"S\u00edndrome cardiorrenal en la insuficiencia cardiaca aguda: Revisando paradigmas","volume":"68","author":"Santas","year":"2015","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","article-title":"Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials)","volume":"119","author":"Tromp","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalisation in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jchf.2016.06.007","article-title":"Carbohydrate Antigen-125\u2013Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study","volume":"4","author":"Bosch","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_23","first-page":"1","article-title":"Improvement of left ventricular ejection fraction in patients with heart failure with reduced ejection fraction: Predictors and clinical impact","volume":"161","author":"Prats","year":"2023","journal-title":"Med. Cl\u00ednica"},{"key":"ref_24","first-page":"31","article-title":"Epidemiology and treatment of heart failure in SPAIN: The HF-PATHWAYS study","volume":"75","author":"Palacios","year":"2022","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: Data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Delgado-Jim\u00e9nez, J.F., Segovia Cubero, J., Almenar-Bonet, L., de Juan-Bagud\u00e1, J., Lara-Padr\u00f3n, A., Garc\u00eda-Pinilla, J.M., Bonilla-Palomas, J.L., L\u00f3pez-Fern\u00e1ndez, S., Mirabet-P\u00e9rez, S., and G\u00f3mez-Otero, I. (2022). Prevalence, incidence and outcomes of hyperkalaemia in patients with chronic heart failure and reduced ejection fraction from a Spanish multicentre study: SPANIK-HF design and baselines characteristics. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051170"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur. J. Heart Fail."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:25:52Z","timestamp":1784528752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/3\/402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medsci14030402"],"URL":"https:\/\/doi.org\/10.3390\/medsci14030402","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}